Shajini

In Today’s NeuroPulse, the neurology sector advanced across multiple fronts, with fresh capital flowing into mental health drug development, early clinical milestones reached in brain cancer and neurodegeneration, and regulators extending approvals that lower risk in pediatric imaging and neuromodulation. From nine-figure biotech launches and oversubscribed neurotech seed rounds to first-in-human dosing, personalized spinal cord … Read more

NeuroPulse: Today’s Three Signals The neurology and neurodegeneration landscape is converging around execution rather than exploration. Today’s signals show how late-stage regulatory precision, platform-driven RNA partnerships, and regulator-grade real-world evidence are reshaping the path from discovery to durable market access. Across ALS, Alzheimer’s disease, and RNA-based therapeutics, stakeholders are tightening alignment between data, infrastructure, and … Read more

Regulatory momentum, precision diagnostics, and late-stage CNS execution accelerate across neurology Today’s NeuroPulse reflects a neurology sector translating scientific validation into regulatory action, late-stage execution, and scalable infrastructure. Across Alzheimer’s disease, stroke, autism, ALS, epilepsy, and rare neurodevelopmental conditions, the common thread is clear: platforms enabling earlier diagnosis, biologically targeted intervention, and real-world evidence generation … Read more

Today’s NeuroPulse tracks critical momentum across neurology, neurotechnology, and CNS drug development, with regulatory clearances, late-stage clinical readouts, and platform expansions reshaping near-term treatment and access dynamics. From FDA progress in epilepsy neuromodulation and adaptive sleep apnea devices to Phase 2 and Phase 3 data in Alzheimer’s disease, social anxiety, and pediatric brain cancer, today’s … Read more